CA2959531C - Probes for imaging huntingtin protein - Google Patents

Probes for imaging huntingtin protein Download PDF

Info

Publication number
CA2959531C
CA2959531C CA2959531A CA2959531A CA2959531C CA 2959531 C CA2959531 C CA 2959531C CA 2959531 A CA2959531 A CA 2959531A CA 2959531 A CA2959531 A CA 2959531A CA 2959531 C CA2959531 C CA 2959531C
Authority
CA
Canada
Prior art keywords
imaging agent
dihydro
optionally substituted
pyridin
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2959531A
Other languages
English (en)
French (fr)
Other versions
CA2959531A1 (en
Inventor
Celia Dominguez
John Wityak
Jonathan Bard
Christopher John Brown
Thomas Martin Krulle
Daniel CLARK-FREW
Sarah HAYES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHDI Foundation Inc
Original Assignee
CHDI Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHDI Foundation Inc filed Critical CHDI Foundation Inc
Publication of CA2959531A1 publication Critical patent/CA2959531A1/en
Application granted granted Critical
Publication of CA2959531C publication Critical patent/CA2959531C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
CA2959531A 2014-08-29 2015-08-28 Probes for imaging huntingtin protein Active CA2959531C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043644P 2014-08-29 2014-08-29
US62/043,644 2014-08-29
PCT/US2015/047396 WO2016033436A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Publications (2)

Publication Number Publication Date
CA2959531A1 CA2959531A1 (en) 2016-03-03
CA2959531C true CA2959531C (en) 2023-01-10

Family

ID=55400644

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2959531A Active CA2959531C (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Country Status (20)

Country Link
US (2) US11071793B2 (enExample)
EP (1) EP3186241B1 (enExample)
JP (3) JP2017527559A (enExample)
KR (1) KR102410760B1 (enExample)
CN (2) CN118005611A (enExample)
AU (1) AU2015308765B2 (enExample)
BR (1) BR112017004136B1 (enExample)
CA (1) CA2959531C (enExample)
DK (1) DK3186241T3 (enExample)
EA (1) EA037275B1 (enExample)
ES (1) ES2841746T3 (enExample)
HR (1) HRP20202032T1 (enExample)
HU (1) HUE052892T2 (enExample)
IL (1) IL250805B (enExample)
MX (2) MX383202B (enExample)
PL (1) PL3186241T3 (enExample)
PT (1) PT3186241T (enExample)
SG (1) SG11201701578YA (enExample)
SI (1) SI3186241T1 (enExample)
WO (1) WO2016033436A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX386798B (es) 2014-08-29 2025-03-19 Chdi Foundation Inc Sondas para la proyección de imagen de la proteína huntingtina.
KR102586736B1 (ko) 2014-08-29 2023-10-11 씨에이치디아이 파운데이션, 인코포레이티드 헌팅틴을 단백질 영상화하기 위한 프로브
CA2959505A1 (en) 2014-08-29 2016-03-03 Chdi Foundation, Inc. Probes for imaging huntingtin protein
US11071793B2 (en) 2014-08-29 2021-07-27 Chdi Foundation, Inc. Probes for imaging huntingtin protein
EP3340796B1 (en) 2015-08-28 2021-04-21 CHDI Foundation, Inc. Probes for imaging huntingtin protein
EP3509588B1 (en) 2016-09-12 2023-06-07 Integral Health,Inc. Bicyclic compounds useful as gpr120 modulators
KR102537985B1 (ko) 2016-09-12 2023-05-30 인테그랄 헬스 인코퍼레이티드 Gpr120 조정제로서 유용한 단환형 화합물
WO2020176424A1 (en) 2019-02-25 2020-09-03 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
US11992535B2 (en) 2019-12-18 2024-05-28 Chdi Foundation, Inc. Compounds and probes for imaging huntingtin protein
CN116075512A (zh) * 2020-06-11 2023-05-05 Chdi基金会股份有限公司 用于对亨廷顿蛋白成像的杂环化合物和显像剂
WO2022216947A1 (en) * 2021-04-08 2022-10-13 Chdi Foundation, Inc. Isoindolinone compounds and imaging agents for imaging huntingtin protein

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726197A (en) * 1992-11-02 1998-03-10 Syntex (U.S.A.) Inc. Isoindolinyl derivatives
YU86801A (sh) 1999-06-10 2004-07-15 Warner-Lambert Company Izoindol derivati korisni u inhibiciji agregacije amiloidnih proteina i snimanju amiloidnih naslaga
PL371366A1 (en) * 2002-03-01 2005-06-13 Takeda Pharmaceutical Company Limited Antidepressant
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
EP2573080A1 (en) * 2007-09-27 2013-03-27 The United States of America, as Represented by the Secretary, Department of Health and Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2009072581A1 (ja) * 2007-12-05 2009-06-11 Aska Pharmaceutical Co., Ltd. ラクタム化合物又はその塩及びppar活性化剤
WO2010104324A2 (ko) * 2009-03-10 2010-09-16 한국과학기술연구원 베타-아밀로이드 집적체 및 피브릴에 우수한 결합 친화도를 가지는 할로겐화 이소인돌론 화합물, 및 이의 제조 방법 및 용도
MX360323B (es) 2012-04-25 2018-10-29 Raqualia Pharma Inc Derivados de pirrolopiridinona como bloqueadores de ttx-s.
CN104903312B (zh) * 2013-10-07 2019-01-29 卡德门企业有限公司 Rho激酶抑制剂
US11071793B2 (en) 2014-08-29 2021-07-27 Chdi Foundation, Inc. Probes for imaging huntingtin protein
CA2959505A1 (en) 2014-08-29 2016-03-03 Chdi Foundation, Inc. Probes for imaging huntingtin protein
KR102586736B1 (ko) 2014-08-29 2023-10-11 씨에이치디아이 파운데이션, 인코포레이티드 헌팅틴을 단백질 영상화하기 위한 프로브
MX386798B (es) 2014-08-29 2025-03-19 Chdi Foundation Inc Sondas para la proyección de imagen de la proteína huntingtina.
EP3340796B1 (en) 2015-08-28 2021-04-21 CHDI Foundation, Inc. Probes for imaging huntingtin protein

Also Published As

Publication number Publication date
IL250805B (en) 2020-08-31
EP3186241A4 (en) 2018-04-18
CN107074817A (zh) 2017-08-18
HRP20202032T1 (hr) 2021-02-19
BR112017004136A2 (pt) 2017-12-12
CA2959531A1 (en) 2016-03-03
JP6843282B2 (ja) 2021-03-17
IL250805A0 (en) 2017-04-30
DK3186241T3 (da) 2021-01-11
EA037275B1 (ru) 2021-03-03
KR20170047348A (ko) 2017-05-04
CN118005611A (zh) 2024-05-10
US20170281804A1 (en) 2017-10-05
PT3186241T (pt) 2021-01-08
KR102410760B1 (ko) 2022-06-20
ES2841746T3 (es) 2021-07-09
US12036291B2 (en) 2024-07-16
PL3186241T3 (pl) 2021-05-17
US11071793B2 (en) 2021-07-27
CN107074817B (zh) 2023-12-15
JP2021088584A (ja) 2021-06-10
BR112017004136B1 (pt) 2022-05-03
JP7042940B2 (ja) 2022-03-28
EP3186241A1 (en) 2017-07-05
HUE052892T2 (hu) 2021-05-28
JP2017527559A (ja) 2017-09-21
EA201790432A1 (ru) 2017-09-29
SG11201701578YA (en) 2017-03-30
MX2021005891A (es) 2021-06-23
EP3186241B1 (en) 2020-10-07
MX383202B (es) 2025-03-13
MX2017002704A (es) 2017-10-23
SI3186241T1 (sl) 2021-03-31
JP2020079272A (ja) 2020-05-28
AU2015308765A1 (en) 2017-03-23
AU2015308765B2 (en) 2020-06-04
US20210379211A1 (en) 2021-12-09
WO2016033436A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
US12036291B2 (en) Probes for imaging huntingtin protein
AU2019283999B2 (en) Probes for imaging huntingtin protein
EP3190888B1 (en) Probes for imaging huntingtin protein
EA035646B1 (ru) Зонды для визуализации белка хантингтина
CA2995847C (en) Probes for imaging huntingtin protein
HK1240582A1 (en) Probes for imaging huntington protein
HK1240582B (en) Probes for imaging huntington protein
HK1241224B (en) Probes for imaging huntingtin protein
HK1241223A1 (en) Probes for imaging huntingtin protein
HK1241223B (en) Probes for imaging huntingtin protein

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200827

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240823

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240823

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250822

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250908